Last reviewed · How we verify
NCT07513961: PAS-DM
Technology-Based Education and Follow-Up in Type 2 Diabetes Management
NA trial testing Technology-Based Diabetes Education and Follow-up System (PAS-DM) in Type 2 Diabetes Mellitus (T2DM) in 112 participants. Completed in 15 March 2022.
15 March 2022
Quick facts
| Lead sponsor | Alanya Alaaddin Keykubat University |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | supportive care |
| Enrollment | 112 |
| Start date | 15 March 2021 |
| Primary completion | 15 March 2022 |
| Estimated completion | 15 March 2022 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Technology-Based Diabetes Education and Follow-up System (PAS-DM)
Conditions studied
- Type 2 Diabetes Mellitus (T2DM) — all drugs for Type 2 Diabetes Mellitus (T2DM) →
- Diabetes Self-management — all drugs for Diabetes Self-management →
- Glycemic Control — all drugs for Glycemic Control →
Sponsor
Alanya Alaaddin Keykubat University
Who can join
Adults 18 to 70, any sex, with Type 2 Diabetes Mellitus (T2DM) or Diabetes Self-management. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to evaluate whether a nurse-led, technology-based education and follow-up program can improve diabetes management in individuals with type 2 diabetes. Participants were randomly assigned to two groups. The intervention group received structured diabetes education and ongoing support through a digital system (Patient Follow-up and Diabetes Management System) for six months. This system provided regular reminders and guidance related to medication use, healthy eating, and physical activity. The control group received standard clinical care without additional digital support. The main objective of the study is to determine whether this technology-supported approach can improve blood sugar control (HbA1c), self-management behaviors, and other health outcomes compared to usual care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07513961
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes Mellitus (T2DM)
Currently open trials in the same condition.
- NCT07533539 — Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration · Phase 1 · recruiting
- NCT07366775 — A Telenursing Program to Support Diabetes Self-Management · NA · active not recruiting
- NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
- NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
- NCT07442006 — Glycemic Variability of Combination Therapies in T2DM · Phase 4 · recruiting
Other Alanya Alaaddin Keykubat University trials
Trials by the same sponsor.
- NCT05670080 — Does MI Have a Therapeutic Role in Arthroscopic Rotator Cuff Repair? · NA · suspended
- NCT07417436 — Effects of Graded Motor Imagery in Individuals With Foot/Ankle Osteoarthritis · NA · recruiting
- NCT06655753 — Craniocervical Dysfunction Index in Patients With Temporomandibular Joint Dysfunction · not yet recruiting
- NCT06634212 — The Dubousset Functional Test in Total Knee Arthloplasty · not yet recruiting
- NCT07542444 — Craniosacral Osteopathic Treatment for Chronic Sinusitis · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07513961 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Alanya Alaaddin Keykubat University
- Last refreshed: 7 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07513961.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing